Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388857 | 0.97 | F10 (0.58) | F10KCNH2KLKB1 | |
| SCHEMBL5399425 | 0.88 | F10 (0.66) | F10KCNH2SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3165956 | 0.85 | F10 (0.65) | F10KCNH2SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL6585701 | 0.84 | F10 (0.59) | F10KCNH2SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4857507 | 0.84 | F10 (0.66) | F10KCNH2SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5392608 | 0.84 | F10 (0.79) | F10KCNH2SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4848484 | 0.83 | F10 (0.65) | F10KCNH2SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5399476 | 0.83 | F10 (0.68) | F10 | |
| SCHEMBL8356569 | 0.83 | F10 (0.64) | F10KCNH2SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3166031 | 0.82 | F10 (0.61) | F10KCNH2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163938-B2 | Substituted carboxamides | ELI LILLY AND COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163938-B2 | Substituted carboxamides | ELI LILLY AND COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163938-B2 | Substituted carboxamides | ELI LILLY AND COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-20040058959-A1 | Substituted carboxamides | HERRON DAVID KENT (US) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058959-A1 | Substituted carboxamides | F11, F12, TFPI | F10 16/4885KCNH2 2069/4885SMN1; SMN2 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.